The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cardiac prosthetic devices market reached a value of US$ 5.4 Billion in 2020. Looking forward, the market is expected to reach a value of US$ 8.9 Billion by 2026, growing at a CAGR of 8.60% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Cardiac prosthetic devices refer to artificial devices that are implanted permanently or temporarily for repairing and replacing damaged heart tissues. Prosthetic heart valves, ventricular assist devices, pacemakers and annuloplasty rings are some of the commonly used cardiac prosthetic devices. Heart valves, including mechanical, tissue (stented/stent-less) and transcatheter valves, are used to prevent retrograde blood flow and leakages. On the other hand, pacemakers are used for maintaining a stable heart rate using electrical impulses. These devices are configured to mimic the normal functioning of cardiovascular organs, and they also aid in preventing further blockages in the heart valves.
Owing to the sedentary lifestyles led by a majority of the population, coupled with their unhealthy dietary habits, there is an increasing prevalence of cardiovascular diseases (CVDs) and various heart ailments, such as cardiomyopathy and Coronary Artery Disease (CAD) across various regions. In line with this, the rising number of individuals with Marfan syndrome, which affects the heart and lungs, along with other vital organs in the body, is also contributing to the market growth. People with this inherited disease of connective tissues endure a damaged aorta and mitral valve prolapse, which may eventually require cardiac prosthetic device implantation as a treatment option for the effective working of the heart. Furthermore, various technological advancements, such as the development of compact pacemakers and suture-less valve replacements, are acting as another growth-inducing factor. These devices are manufactured using durable and biocompatible raw materials and can be implanted into the patient’s body through minimally invasive (MI) procedures. Other factors, including the growing geriatric population, improving healthcare infrastructure, rising awareness regarding the available treatment for CVDs and extensive research and development (R&D) activities, are projected to drive the market in the upcoming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cardiac prosthetic devices market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product type and end-user.
Breakup by Product Type:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Biotronik, Boston Scientific Corporation, Edwards Lifesciences Corporation, Lepu Medical Technology Co. Ltd., Medtronic Inc., Meril Life Sciences Pvt. Ltd., Siemens Healthcare GmbH, Sorin Group, St. Jude Medical Inc., etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product Type, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Biotronik, Boston Scientific Corporation, Edwards Lifesciences Corporation, Lepu Medical Technology Co. Ltd., Medtronic Inc., Meril Life Sciences Pvt. Ltd., Siemens Healthcare GmbH, Sorin Group and St. Jude Medical Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at